Nicotine effects on cognitive remediation training outcome in people with schizophrenia: A pilot study.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

The present study aimed at augmenting training effects by administering nicotine prior to training sessions.

Every Monday and Thursday, the nicotine group received a nicotine lozenge before the training, and the placebo group a placebo lozenge.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

Twenty-five people with schizophrenia were enrolled in a 10-week, 5 days/week, computerized cognitive training regimen.

Participants were randomized to two treatment groups: nicotine or placebo.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and pilot.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

What Was Measured

Outcome measurements were conducted on a no-lozenge day in weeks 0, 4, 7, and 10, and at 4-week follow-up.

The subject headings attached to it are Cognitive Remediation, Executive Function, Neuropsychological Tests, Nicotine, Pilot Projects, Quality of Life and Schizophrenia.

Author keywords: Cognition and Cognitive remediation training.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2019 (Psychiatry research), a journal based in Ireland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.